• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trends in Apolipoprotein B, Non-High-Density Lipoprotein, and Low-Density Lipoprotein for Adults 60 Years and Older by Use of Lipid-Lowering Medications: United States, 2005 to 2006 Through 2013 to 2014.

作者信息

Carroll Margaret D, Mussolino Michael E, Wolz Michael, Srinivas Pothur R

机构信息

Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, Hyattsville, MD (M.D.C.).

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (M.E.M., M.W., P.R.S.).

出版信息

Circulation. 2018 Jul 10;138(2):208-210. doi: 10.1161/CIRCULATIONAHA.117.031982.

DOI:10.1161/CIRCULATIONAHA.117.031982
PMID:29986963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6047888/
Abstract
摘要

相似文献

1
Trends in Apolipoprotein B, Non-High-Density Lipoprotein, and Low-Density Lipoprotein for Adults 60 Years and Older by Use of Lipid-Lowering Medications: United States, 2005 to 2006 Through 2013 to 2014.2005年至2006年至2013年至2014年美国60岁及以上成年人使用降脂药物后载脂蛋白B、非高密度脂蛋白和低密度脂蛋白的变化趋势
Circulation. 2018 Jul 10;138(2):208-210. doi: 10.1161/CIRCULATIONAHA.117.031982.
2
Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).载脂蛋白 B 与低密度脂蛋白胆固醇和非高密度脂蛋白胆固醇的不匹配与动脉粥样硬化多民族研究（MESA）中的冠状动脉钙化有关。
J Clin Lipidol. 2020 Jan-Feb;14(1):109-121.e5. doi: 10.1016/j.jacl.2019.11.005. Epub 2019 Nov 29.
3
Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis.非高密度脂蛋白胆固醇与 LDL 颗粒测量值之间的差异：来自动脉粥样硬化多民族研究的结果。
Atherosclerosis. 2013 Aug;229(2):517-23. doi: 10.1016/j.atherosclerosis.2013.03.012. Epub 2013 Mar 26.
4
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.米泊美生，一种载脂蛋白 B 合成抑制剂，可降低高心血管风险严重高胆固醇血症患者的致动脉粥样硬化脂蛋白：一项随机、双盲、安慰剂对照试验。
J Am Coll Cardiol. 2013 Dec 10;62(23):2178-84. doi: 10.1016/j.jacc.2013.07.081. Epub 2013 Sep 4.
5
Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.氟伐他汀对高胆固醇血症患者中密度脂蛋白（残粒）及其他脂蛋白水平的影响。
Am J Cardiol. 1995 Jul 13;76(2):129A-135A. doi: 10.1016/s0002-9149(05)80035-9.
6
Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).依泽替米贝/辛伐他汀或阿托伐他汀治疗代谢综合征伴或不伴动脉粥样硬化性血管疾病患者时特定 LDL 胆固醇、非高密度脂蛋白胆固醇载脂蛋白 B 和高敏 C 反应蛋白水平的达成（来自 VYMET 研究）。
J Clin Lipidol. 2011 Nov-Dec;5(6):474-82. doi: 10.1016/j.jacl.2011.06.004. Epub 2011 Jun 15.
7
Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.载脂蛋白 B 和非高密度脂蛋白胆固醇在 2 型糖尿病且低密度脂蛋白胆固醇控制良好的个体中显示出高致动脉粥样硬化性。
Lipids Health Dis. 2020 Jun 6;19(1):127. doi: 10.1186/s12944-020-01292-w.
8
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.阿利西尤单抗治疗 2 型糖尿病合并动脉粥样硬化性心血管疾病患者：ODYSSEY DM-DYSLIPIDEMIA 和 DM-INSULIN 研究分析。
Cardiovasc Diabetol. 2019 Nov 9;18(1):149. doi: 10.1186/s12933-019-0951-9.
9
Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.年龄、腹型肥胖和基线高敏 C 反应蛋白与代谢综合征患者接受依折麦布/辛伐他汀和阿托伐他汀治疗后低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和载脂蛋白 B 的反应相关。
J Clin Lipidol. 2013 Jul-Aug;7(4):292-303. doi: 10.1016/j.jacl.2013.03.007. Epub 2013 Apr 3.
10
Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study.非裔美国人和高加索人中辛伐他汀治疗反应的表型预测因素：胆固醇与药物遗传学（CAP）研究
Am J Cardiol. 2006 Mar 15;97(6):843-50. doi: 10.1016/j.amjcard.2005.09.134. Epub 2006 Jan 27.

引用本文的文献

1
Increasing likelihood of prescribing recommended lipid management: Primary care providers' participation in cardiology continuing medical education.提高推荐血脂管理处方的可能性：初级保健提供者参与心脏病学继续医学教育。
Can Fam Physician. 2022 Jan;68(1):39-46. doi: 10.46747/cfp.680139.

本文引用的文献

1
Trends in Total Cholesterol, Triglycerides, and Low-Density Lipoprotein in US Adults, 1999-2014.1999 - 2014年美国成年人总胆固醇、甘油三酯和低密度脂蛋白的变化趋势
JAMA Cardiol. 2017 Mar 1;2(3):339-341. doi: 10.1001/jamacardio.2016.4396.
2
Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).强化他汀类药物治疗急性冠脉综合征（从限制 ACS 患者血脂治疗不足用瑞舒伐他汀的研究[LUNAR]）对致动脉粥样硬化脂蛋白胆固醇与载脂蛋白 B 比值的影响。
Am J Cardiol. 2013 Feb 15;111(4):506-9. doi: 10.1016/j.amjcard.2012.10.037. Epub 2012 Dec 10.
3
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
无需使用制备性超速离心机来估算血浆中低密度脂蛋白胆固醇的浓度。
Clin Chem. 1972 Jun;18(6):499-502.